Combining an Effective Rule-based Chatbot With ChatGPT-supported Real-time Question-answer Functions to Promote Seasonal Influenza Vaccination Among Community-dwelling People Aged 65 Years and Above
Combining an Effective Rule-based Chatbot With ChatGPT-supported Real-time Question-answer Functions to Promote Seasonal Influenza Vaccination Among Community-dwelling People Aged 65 Years and Above: a Partially Blinded Randomized Controlled Trial
This study is a partially blinded (outcome assessors and data analysts) and parallel-group randomized controlled trial. Community-dwelling people aged ≥65 years who have not received the SIV for the approaching flu season will be randomized evenly (1:1) into either the intervention group or the control group. During the intervention period, the intervention group will have access to the hybrid combination of a rule-based chatbot (SIV-Chatbot) with the ChatGPT-supported real-time Question & Answer (QA) functions, while the control group will have access only to the SIV-Chatbot.
The SIV-Chatbot will deliver the same interventions for both groups. The number of intervention sessions (four) and timing (week 0, 2, 4 & 6) will also be the same. In the intervention group, the hybrid Chatbot will invite the participants to raise open-ended questions related to SIV using flexible methods (such as voice messages, typing with keyboards, or handwriting) at each session. The ChatGPT will answer these questions immediately in the format of text messages. The functions can be used repeatedly throughout the intervention period (weeks 0-6), and participants will be free to spend as much time as they want on such functions.
Telephone interviews will be conducted at baseline (T0), after completion of the intervention (T1), and six months after T1 (T2). The primary outcome will be the self-reported SIV uptake measured at T2. The research team will validate that outcome by requesting the participants upload an image of their SIV receipt, while hiding their personal identification, via the WhatsApp account used in this study.
Tutkimuksen yleiskatsaus
Tila
Ehdot
Interventio / Hoito
Opintotyyppi
Ilmoittautuminen (Arvioitu)
Vaihe
- Ei sovellettavissa
Yhteystiedot ja paikat
Opiskeluyhteys
- Nimi: Zixin Wang, PhD
- Puhelinnumero: +852 22528474
- Sähköposti: wangzx@cuhk.edu.hk
Osallistumiskriteerit
Kelpoisuusvaatimukset
Opintokelpoiset iät
Hyväksyy terveitä vapaaehtoisia
Sukupuolet, jotka voivat opiskella
Kuvaus
Inclusion Criteria:
- aged ≥65 years
- possession of a Hong Kong ID
- able to speak and comprehend Cantonese
- have a smartphone with internet access
- have either installed or are willing to install WhatsApp on their smartphone
- have not taken seasonal influenza vaccination for the approaching flu season
Exclusion Criteria:
- score ≤16 in the validated telephone version of the Cantonese Mini-Mental State Examination (T-CMMSE)
- either blindness or deafness
- with known contraindications to the SIV as indicated by the Hong Kong Centre for Health Protection (e.g., history of severe allergic reactions to any of the vaccine component or a previous dose of SIV and bleeding disorders)
Opintosuunnitelma
Miten tutkimus on suunniteltu?
Suunnittelun yksityiskohdat
- Ensisijainen käyttötarkoitus: Terveyspalvelututkimus
- Jako: Satunnaistettu
- Inventiomalli: Rinnakkaistehtävä
- Naamiointi: Yksittäinen
Aseet ja interventiot
Osallistujaryhmä / Arm |
Interventio / Hoito |
|---|---|
|
Kokeellinen: Intervention group
Have access to the hybrid combination of a rule-based chatbot (SIV-Chatbot) with the ChatGPT-supported real-time QA functions |
After assessing participants' stage of change (SOC) regarding SIV uptake, the rule-based component (SIV-Chatbot) will deliver online interventions tailored to their current SOC. There will be four intervention sessions at week 0, 2, 4 and 6. In addition, the hybrid Chatbot will invite the participants to raise open-ended questions related to SIV using flexible methods at each session. The ChatGPT will answer these questions immediately in the format of text messages. The functions can be used repeatedly throughout the intervention period (weeks 0-6), and participants will be free to spend as much time as they want on such functions. |
|
Active Comparator: Control group
Have access only to a rule-based chatbot (SIV-Chatbot) |
After assessing participants' stage of change (SOC) regarding SIV uptake, the rule-based chatbot (SIV-Chatbot) will deliver online interventions tailored to their current SOC. There will be four intervention sessions at week 0, 2, 4 and 6. |
Mitä tutkimuksessa mitataan?
Ensisijaiset tulostoimenpiteet
Tulosmittaus |
Toimenpiteen kuvaus |
Aikaikkuna |
|---|---|---|
|
Uptake of seasonal influenza vaccination
Aikaikkuna: Six months after completion of the intervention
|
The primary outcome will be the self-reported seasonal influenza vaccination uptake measured at T2 (six months after completion of the intervention). The research team will validate that outcome by requesting the participants upload an image of their receipt. |
Six months after completion of the intervention
|
Toissijaiset tulostoimenpiteet
Tulosmittaus |
Toimenpiteen kuvaus |
Aikaikkuna |
|---|---|---|
|
Stage of change related to seasonal influenza vaccination uptake
Aikaikkuna: T0 (baseline), T1 (after completion of intervention), and T2 (six months after completion of the intervention)
|
Participants' SOC will be measured at T0 (baseline), T1 (after completion of intervention), and T2 (six months after completion of the intervention) by using validated questions |
T0 (baseline), T1 (after completion of intervention), and T2 (six months after completion of the intervention)
|
|
Knowledge and attitudes related to seasonal influenza vaccination
Aikaikkuna: T0 (baseline) and T2 (6 months after completion of the intervention)
|
Knowledge and attitudes will be measured at T0 (baseline) and T2 (6 months after completion of the intervention) by validated tools |
T0 (baseline) and T2 (6 months after completion of the intervention)
|
Yhteistyökumppanit ja tutkijat
Sponsori
Opintojen ennätyspäivät
Opi tärkeimmät päivämäärät
Opiskelun aloitus (Arvioitu)
Ensisijainen valmistuminen (Arvioitu)
Opintojen valmistuminen (Arvioitu)
Opintoihin ilmoittautumispäivät
Ensimmäinen lähetetty
Ensimmäinen toimitettu, joka täytti QC-kriteerit
Ensimmäinen Lähetetty (Todellinen)
Tutkimustietojen päivitykset
Viimeisin päivitys julkaistu (Todellinen)
Viimeisin lähetetty päivitys, joka täytti QC-kriteerit
Viimeksi vahvistettu
Lisää tietoa
Tähän tutkimukseen liittyvät termit
Muut tutkimustunnusnumerot
- GRF14611325
Yksittäisten osallistujien tietojen suunnitelma (IPD)
Aiotko jakaa yksittäisten osallistujien tietoja (IPD)?
IPD-suunnitelman kuvaus
The data presented in this study are available from the corresponding author upon request. The data are not publicly available as they contain sensitive personal information.
Lääke- ja laitetiedot, tutkimusasiakirjat
Tutkii yhdysvaltalaista FDA sääntelemää lääkevalmistetta
Tutkii yhdysvaltalaista FDA sääntelemää laitetuotetta
Nämä tiedot haettiin suoraan verkkosivustolta clinicaltrials.gov ilman muutoksia. Jos sinulla on pyyntöjä muuttaa, poistaa tai päivittää tutkimustietojasi, ota yhteyttä register@clinicaltrials.gov. Heti kun muutos on otettu käyttöön osoitteessa clinicaltrials.gov, se päivitetään automaattisesti myös verkkosivustollemme .